Drug intelligence / Profile preview

KLA318-2

Development stage: Phase 1
Lead developer: Hunan Kelun Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

KLA318-2 is a small molecule chemical drug developed by Hunan Kelun Pharmaceutical for the treatment of postoperative pain. It is formulated as a nanocrystal injection, designed for intravenous administration. Its mechanism of action, molecular target, and broad pharmacological class have not been publicly disclosed. Clinical development is at phase 1, with trials focused on evaluating safety, tolerability, and pharmacokinetics in healthy participants[1][4][7].

Other names: KLA318-2 nanocrystal injectionKLA-318-2 nanocrystal injectionKLA 318-2 nanocrystal injection

Beyond the preview

Go deeper on KLA318-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLA318-2.

Explore the full profile